Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Antibodies
Filter     Order     Display # 
Date Item Title
05 Apr 2006 FDA Grants Priority Review of REMICADE(R) for the Treatment of Children with Active Crohn's Disease
04 Apr 2006 Seattle Genetics Reports Continued Advances with SGN-70 and Its ADC Technology at the AACR Annual Meeting
04 Apr 2006 CancerVax Presents Preclinical Data Demonstrating Tumor Inhibition by D93, a Novel Anti-Angiogenic Monoclonal Antibody
04 Apr 2006 Astellas to Acquire AMEVIVE (alefacept)
04 Apr 2006 Newly Published Data Show Early Use Of Avonex Delayed The Risk Of Multiple Sclerosis For Up To 5 Years
03 Apr 2006 CancerVax Announces FDA Approval of IND for Novel Anti-Angiogenic Antibody D93
03 Apr 2006 Preclinical Studies Presented at AACR Meeting Show Potential of Peregrine's Tarvacin(TM) Plus Radiation or Chemotherapy to Increase Survival in Resistant Breast Cancer and Brain Cancer
03 Apr 2006 ImClone Systems Reports Advancements in Pre-Clinical and Clinical-Stage Antibody Research Programs at AACR Annual Meeting; Pre-Clinical Study Suggests that ERBITUX(R) (Cetuximab) has Novel Mechanism of Action
03 Apr 2006 Inhibitex Reports Top-Line Results in Phase III Study of Veronate(R)
03 Apr 2006 ARIUS Research Signs Anti-Cancer Antibody Discovery Deal with Takeda
03 Apr 2006 Randomized Phase 3 Trial Shows Panitumumab Significantly Improved Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
03 Apr 2006 Merck KGaA Receives EMEA Approval for Erbitux in Head and Neck Cancer
31 Mar 2006 Medarex Announces Initiation of Registrational Trial for Ipilimumab (MDX-010) as Monotherapy in Previously-Treated Metastatic Melanoma Patients
30 Mar 2006 Amgen and Abgenix Complete Biologics License Application for FDA Approval of Panitumumab
30 Mar 2006 Genentech and Biogen Idec Submit Supplemental Biologics License Application for First-Line Use of Rituxan in Low-Grade or Follicular CD20-Positive B-Cell Non-Hodgkin’s Lymphoma
30 Mar 2006 Biogen Idec and Elan Announce Re-Initiation of TYSABRI(R) Clinical Trial Dosing in Multiple Sclerosis
30 Mar 2006 Elusys Therapeutics Successfully Completes Human Clinical Study of Anthrax Therapeutic, Anthim(TM)
28 Mar 2006 Ono and Medarex Enter Into Second Collaboration for the Development of a Fully Human Antibody Therapeutic
28 Mar 2006 YM BioSciences' partner, Oncoscience AG, cleared for Phase III trial in Germany with nimotuzumab
28 Mar 2006 University of Pittsburgh Clinical Study to Test Antibody Therapy for Patients With Severe Ulcerative Colitis
25 Mar 2006 Biowa Licenses Potelligent™ Technology To Genentech For Use In Antibody Development
24 Mar 2006 Algeta publish results of new thorium-227 mAb conjugate
24 Mar 2006 YM Biosciences Initiates Non-Small-Cell Lung Cancer Trial With Nimotuzumab
24 Mar 2006 Licensing Agreement for the Development, Manufacturing and Marketing of Anti-human Osteopontin Antibodies
23 Mar 2006 GammaCan Announces Positive Pre-IND Meeting with the U.S. FDA Regarding VitiGam - the Company's Novel Treatment for Metastatic Malignant Melanoma
22 Mar 2006 Biogen Idec And Elan Announce That FDA Will Extend Regulatory Review Period For The Reintroduction Of Tysabri® For Multiple Sclerosis
22 Mar 2006 Genmab Reports ACR50 And ACR70 Results In HuMax-CD20 Study To Treat RA
18 Mar 2006 Genentech Provides Updates At Annual Investment Meeting
16 Mar 2006 MorphoSys and Japanese Pharmaceutical Group Daiichi Sankyo Form Broad Alliance to Develop Novel Antibody Therapies
16 Mar 2006 Statement re Clinical Volunteers and TGN 1412
14 Mar 2006 Argos Therapeutics and Novo Nordisk announce agreement to develop treatment for systemic autoimmune disorders
14 Mar 2006 ALEXION Updates Previously Announced Phase III Results for PRIMO-CABG2 Study
14 Mar 2006 SDSU Study Shows Antibody May Reduce or Eliminate Tumors
11 Mar 2006 Genmab Announces Update On AMG 714 Program With Amgen
09 Mar 2006 REMICADE(R) Is First Biologic Approved In European Union To Treat Ulcerative Colitis
09 Mar 2006 FDA Advisory Committee Unanimously Recommends Reintroduction Of Tysabri® For The Treatment Of Relapsing Forms Of Multiple Sclerosis
08 Mar 2006 AC Immune identifies Clinical Lead Compounds for Alzheimer’s Disease Treatment.
08 Mar 2006 77% Achieve Acr20 With Genmab’s Humax-Cd20 In Rheumatoid Arthritis Study
07 Mar 2006 Phase III Clinical Study Shows Vivaglobin®, a New Subcutaneous Immunoglobulin, Is Safe and Effective In Treating Patients With Primary Immunodeficiency
06 Mar 2006 PharmAthene and Medarex Receive Orphan Drug Designation for Valortim(TM) to Treat Anthrax Infection
04 Mar 2006 REMICADE® (infliximab) Phase 3 Data Show Rapid And Significant Improvement And Long-Term Response In The Treatment Of Moderate To Severe Psoriasis
03 Mar 2006 Bradmer Completes Manufacturing Agreement With Laureate Pharma
02 Mar 2006 UCB Submits Biologics License Application to FDA for New Treatment in Crohn's Disease
02 Mar 2006 Novartis seeks European approval of Lucentis® for the treatment of patients with wet age-related macular degeneration (AMD)
02 Mar 2006 FDA Approves ERBITUX(R) (Cetuximab) for Treatment of Head and Neck Cancer
02 Mar 2006 CancerVax Files IND for Novel Anti-Angiogenic Antibody D93
02 Mar 2006 Tysabri® Two-Year Phase Iii Multiple Sclerosis Clinical Trial Results And Safety Evaluation Published In New England Journal Of Medicine
01 Mar 2006 Northwest Biotherapeutics Presents New Data on Monoclonal Antibody to CXCR4
01 Mar 2006 MorphoSys and Roche Expand Therapeutic Antibody Partnership
01 Mar 2006 FDA Approves Rituxan - The First Targeted B-Cell Therapy for Treatment of Moderate-to-Severe Rheumatoid Arthritis
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>
Results 951 - 1000 of 1053

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Emerging Diabetes Drugs

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics